Welcome to the international HTA database

Showing [20001 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2000	Institute for Clinical Systems Improvement (ICSI)	Transmyocardial laser therapy for severe refractory angina
1998	Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT)	Transmyocardial revascularisation by laser (systematic review, expert panel)
1998	University HealthSystem Consortium (UHC)	Transmyocardial revascularization
2002	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	Transmyocardial revascularization for treatment of angina
1996	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	Transmyocardial revascularization with laser
2011	Health Technology Assessment Section, Ministry of Health Malaysia (MaHTAS)	Transnasal oesophagoscopy (TNE)
1998	Institute of Technology Assessment (ITA)	Transnational analysis of the socio-economic impact of Alzheimer's disease (AD) in the European Union
2005	National Institute for Clinical Excellence (NICE)	Transobturator foramen procedures for stress urinary incontinence
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Transobturator slings for urinary incontinence: clinical effectiveness and guidelines
2002	Medical Services Advisory Committee (MSAC)	Transoesophageal echocardiography
2015	Canadian Agency for Drugs and Technologies in Health (CADTH)	Transoral robotic surgery: a review of clinical and cost-effectiveness
2022	Norwegian Institute of Public Health (NIPH)	Transperineal compared with transrectal biopsy on suspected prostate cancer: a health technology assessment
2010	National Institute for Health and Clinical Excellence (NICE)	Transperineal template biopsy of the prostate
2002	HAYES, Inc.	Transperineal ultrasound-guided brachytherapy for early-stage prostate cancer
2005	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Transplantation of allogeneic hematopoietic stem cells from unrelated donors in adult patients at the MUHC
2003	The Swedish Council on Health Technology Assessment (SBU)	Transplantation of cultured skin (Apligraf(R)) in treating venous leg ulcers - early assessment briefs (Alert)
2001	The Swedish Council on Health Technology Assessment (SBU)	Transplantation of stem cells from umbilical cord blood - early assessment briefs (Alert)
1994	Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ)	Transplantation with bone marrow not derived from HLA identical family donors for the treatment of adults and children with hemato-oncologic and congenital diseases - primary research
2002	Blue Cross Blue Shield Association (BCBS)	Transplanting adult patients with hematopoietic stem cells from placental and umbilical cord blood
2006	National Institute for Clinical Excellence (NICE)	Transport interventions promoting safe cycling and walking: evidence briefing
2012	NIHR Horizon Scanning Centre (NIHR HSC)	Transportable haemodialysis machines for established renal failure
2007	New Zealand Health Technology Assessment (NZHTA)	Transportation of emergency patients
2003	Institute for Clinical Effectiveness and Health Policy (IECS)	Transpupillary thermotherapy
2004	National Institute for Clinical Excellence (NICE)	Transpupillary thermotherapy for age-related macular degeneration
2002	NIHR Horizon Scanning Centre (NIHR HSC)	Transpupillary thermotherapy for age-related macular degeneration - horizon scanning review
2002	HAYES, Inc.	Transpupillary thermotherapy for choroidal tumors and macular degeneration
2011	Center for Evidence-based Practice (CEP)	Transradial access for cardiac catheterization
2013	HAYES, Inc.	Transradial, transbrachial, and transulnar approaches for coronary angiography and intervention
1994	Conseil d'Evaluation des Technologies de la Santé du Quebec (CETS)	Transurethral diathermy for benign prostatic hypertrophy: update -nonsystematic review
2003	National Institute for Clinical Excellence (NICE)	Transurethral electrovaporisation of the prostate
2012	Medical Services Advisory Committee (MSAC)	Transurethral injection of botulinum toxin into the ladder wall for urinary incontinence due to neurogenic detrusor overactivity
2000	HAYES, Inc.	Transurethral microwave thermotherapy
2007	HAYES, Inc.	Transurethral microwave thermotherapy
2000	Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT)	Transurethral microwave thermotherapy (TUMT) for benign prostatic hyperplasia
2002	Medical Services Advisory Committee (MSAC)	TransUrethral Needle Ablation (TUNA) for the treatment of benign prostatic hyperplasia
2005	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	Transurethral needle ablation (TUNA) in the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis
2001	ECRI	Transurethral needle ablation [TUNA (R)] for benign prostatic hyperplasia
2001	HAYES, Inc.	Transurethral needle ablation therapy
2007	HAYES, Inc.	Transurethral radiofrequency micro-remodeling using the Renessa system (Novasys Medical Inc.) for female stress urinary incontinence
2010	HAYES, Inc.	Transurethral Radiofrequency Micro-Remodeling Using the Renessa System (Novasys Medical Inc.) for Female Stress Urinary Incontinence
2003	National Institute for Clinical Excellence (NICE)	Transurethral radiofrequency needle ablation of the prostate
2011	HAYES, Inc.	Transvaginal ultrasound for measurement of cervical length to predict preterm birth
2016	NIHR Health Technology Assessment programme	TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer
2004	HAYES, Inc.	Trastuzumab (Herceptin (R)) for breast cancer
2007	NIHR Horizon Scanning Centre (NIHR HSC)	Trastuzumab (Herceptin) for advanced gastric cancer
2007	HAYES, Inc.	Trastuzumab (Herceptin) for early breast cancer
2012	NIHR Horizon Scanning Centre (NIHR HSC)	Trastuzumab (Herceptin) for HER2 positive early breast cancer – two year regimen
2010	NIHR Horizon Scanning Centre (NIHR HSC)	Trastuzumab (Herceptin) for HER2 positive early, locally advanced and inflammatory breast cancer - neoadjuvant treatment
2001	The Swedish Council on Health Technology Assessment (SBU)	Trastuzumab (Herceptin) for metastasized breast cancer - early assessment briefs (Alert)
2007	HAYES, Inc.	Trastuzumab (Herceptin) for metastatic cancer
2010	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Trastuzumab (Herceptin) in addition to standard chemotherapy as first-line therapy for advanced gastric cancer
2006	NIHR Horizon Scanning Centre (NIHR HSC)	Trastuzumab (Herceptin) in combination with aromatase inhibitors for stage IV - metastatic breast cancer: horizon scanning technology briefing
2012	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Trastuzumab (Herceptin®)
2012	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Trastuzumab (Herceptin®) 150 mg powder for concentrate for solution for infusion
2003	ECRI	Trastuzumab [Herceptin (R)] for the treatment of breast cancer
2005	NIHR Horizon Scanning Centre (NIHR HSC)	Trastuzumab as adjuvant therapy for early stage breast cancer - horizon scanning review
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Trastuzumab emtansine (Kadcyla) for patients with HER2 positive locally advanced or metastatic relapsed gastric cancers
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Trastuzumab emtansine (KadcylaTM) for previously treated patients with HER2-positive advanced/metastatic breast cancer
2012	NIHR Horizon Scanning Centre (NIHR HSC)	Trastuzumab emtansine in combination with pertuzumab for HER2-positive metastatic breast cancer – first line
2005	Institute for Clinical Effectiveness and Health Policy (IECS)	Trastuzumab for breast cancer treatment
2006	Quality Improvement Scotland (NHS QIS )	Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer
2006	National Institute for Health and Clinical Excellence (NICE)	Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer
2011	NIHR Health Technology Assessment programme	Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction
2011	NIHR Health Technology Assessment programme	Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction
2010	National Institute for Health and Clinical Excellence (NICE)	Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
2009	NIHR Health Technology Assessment programme	Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal
2020	Agency for Care Effectiveness (ACE)	Trastuzumab for treating HER2-positive breast and gastric cancers
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Trastuzumab SC (Herceptin SC) for breast cancer, early or metastatic, HER2 positive - monotherapy or combination therapy, including neo-adjuvant and adjuvant use
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Trastuzumab-DM1 (Herceptin-DM1) for breast cancer, locally advanced or metastatic, HER2 positive - second or third line
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Trastuzumab-emtansine (Kadcyla®) in adjuvant treatment of adult patients with HER-2 positive breast cancer in an early stage
2018	Canary Health Service	Tratamiento nutricional de adultos con insuficiencia renal crónica (IRC) con desnutrición energético-proteica grave no reversible mediante alimentos de consumo ordinario
2011	Agency for Healthcare Research and Quality (AHRQ)	Traumatic brain injury and depression.
2016	The Swedish Council on Health Technology Assessment (SBU)	Traumatic shaking – The role of the triad in medical investigations of suspected traumatic shaking
2015	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Travoprost (Travatan®)
2000	The Swedish Council on Health Technology Assessment (SBU)	Treating asthma and COPD - a systematic review
1999	University of York	Treating head lice and scabies
2001	The Swedish Council on Health Technology Assessment (SBU)	Treating influenza by medication - zanamivir - early assessment briefs (ALERT)
2003	University of York	Treating nocturnal enuresis in children
2003	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	Treating osteoporosis with teriparatide: many unknowns?
2002	Norwegian Knowledge Centre for the Health Services (NOKC)	Treating prostate cancer with brachytherapy
2011	Health Council of the Netherlands Gezondheidsraad (GR)	Treating the effect of child abuse
2010	Institute of Health Economics (IHE)	Treatment for convicted adult male sex offenders
2012	Agency for Healthcare Research and Quality (AHRQ)	Treatment for depression after unsatisfactory response to SSRIs
2008	NIHR Health Technology Assessment programme	Treatment for fibroids: Uterine Artery Embolisation (UAE) or hysterectomy (HOPEFUL) - Primary Research (e.g. trial)
2012	Agency for Healthcare Research and Quality (AHRQ)	Treatment for glaucoma: comparative effectiveness
2012	Agency for Healthcare Research and Quality (AHRQ)	Treatment for glaucoma: comparative effectiveness
2012	Agency for Healthcare Research and Quality (AHRQ)	Treatment for hepatitis C virus infection in adults
2012	Agency for Healthcare Research and Quality (AHRQ)	Treatment for restless legs syndrome
2018	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	Treatment Foster Care Oregon for seriously delinquent adolescents
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Treatment of adult patients with immune thrombocytopenia after failure of first-line therapies
2022	NIHR Health Technology Assessment programme	Treatment of Advanced Glaucoma Study (TAGS): a multicentre randomised controlled trial comparing primary medical treatment with primary trabeculectomy for people with newly diagnosed advanced glaucoma
2001	L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES)	Treatment of age related macular degeneration
2001	The Swedish Council on Health Technology Assessment (SBU)	Treatment of alcohol and drug abuse - an evidence-based review
2012	Canadian Agency for Drugs and Technologies in Health (CADTH)	Treatment of anemia and neutropenia in patients with chronic hepatitis C infection treated with peginterferon-ribavirin based regimens with or without protease inhibitors: a review of the clinical evidence
2005	The Swedish Council on Health Technology Assessment (SBU)	Treatment of anxiety disorders: a systematic review
2013	Agency for Healthcare Research and Quality (AHRQ)	Treatment of atrial fibrillation
1999	Agency for Healthcare Research and Quality (AHRQ)	Treatment of attention-deficit/hyperactivity disorder
1994	L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES)	Treatment of autism
2022	NIHR Health Technology Assessment programme	Treatment of Barth Syndrome by CARDIOlipin MANipulation (CARDIOMAN): a randomised placebo-controlled pilot trial conducted by the nationally commissioned Barth Syndrome Service
1995	Australian Health Technology Advisory Committee (AHTAC)	Treatment of benign prostatic hyperplasia in Australia - some economic considerations